Table of Contents

company-logo

BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.

BioVaxys Technology Dividend Announcement

• BioVaxys Technology does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on BioVaxys Technology dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

BioVaxys Technology Dividend History

BioVaxys Technology Dividend Yield

BioVaxys Technology current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing BioVaxys Technology stock? Use our calculator to estimate your expected dividend yield:

BioVaxys Technology Financial Ratios

P/E ratio-3.45
PEG ratio-0.02
P/B ratio-67.62
ROE322.77%
Payout ratio0.00%
Current ratio0.39
Quick ratio0.39
Cash Ratio0.18

BioVaxys Technology Dividend FAQ

Does BioVaxys Technology stock pay dividends?
BioVaxys Technology does not currently pay dividends to its shareholders.
Has BioVaxys Technology ever paid a dividend?
No, BioVaxys Technology has no a history of paying dividends to its shareholders. BioVaxys Technology is not known for its dividend payments.
Why doesn't BioVaxys Technology pay dividends?
There are several potential reasons why BioVaxys Technology would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will BioVaxys Technology ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While BioVaxys Technology has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is BioVaxys Technology a dividend aristocrat?
BioVaxys Technology is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is BioVaxys Technology a dividend king?
BioVaxys Technology is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is BioVaxys Technology a dividend stock?
No, BioVaxys Technology is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy BioVaxys Technology stocks?
To buy BioVaxys Technology you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy BioVaxys Technology stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.